Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1995 1
1996 3
1997 1
1998 3
1999 1
2000 3
2001 5
2002 3
2003 3
2004 1
2005 4
2006 4
2007 5
2008 4
2009 5
2010 5
2011 5
2012 13
2013 7
2014 2
2015 2
2016 2
2017 3
2018 7
2019 2
2020 3
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

97 results
Results by year
Filters applied: . Clear all
Page 1
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. Among authors: lawrence nj. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).
Hofman MS, Emmett L, Violet J, Y Zhang A, Lawrence NJ, Stockler M, Francis RJ, Iravani A, Williams S, Azad A, Martin A, McJannett M; ANZUP TheraP team, Davis ID. Hofman MS, et al. Among authors: lawrence nj. BJU Int. 2019 Nov;124 Suppl 1:5-13. doi: 10.1111/bju.14876. Epub 2019 Oct 22. BJU Int. 2019. PMID: 31638341 Free article. Clinical Trial.
Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes.
Hesterberg RS, Beatty MS, Han Y, Fernandez MR, Akuffo AA, Goodheart WE, Yang C, Chang S, Colin CM, Alontaga AY, McDaniel JM, Mailloux AW, Billington JMR, Yue L, Russell S, Gillies RJ, Yun SY, Ayaz M, Lawrence NJ, Lawrence HR, Yu XZ, Fu J, Darville LN, Koomen JM, Ren X, Messina J, Jiang K, Garrett TJ, Rajadhyaksha AM, Cleveland JL, Epling-Burnette PK. Hesterberg RS, et al. Among authors: lawrence nj. Blood. 2020 Aug 13;136(7):857-870. doi: 10.1182/blood.2019003257. Blood. 2020. PMID: 32403132
Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity.
Walton K, Fernandez MR, Sagatys EM, Reff J, Kim J, Lee MC, Kiluk JV, Hui JYC, McKenna D Jr, Hupp M, Forster C, Linden MA, Lawrence NJ, Lawrence HR, Pidala J, Pavletic SZ, Blazar BR, Sebti SM, Cleveland JL, Anasetti C, Betts BC. Walton K, et al. Among authors: lawrence nj. JCI Insight. 2020 May 7;5(9):e136437. doi: 10.1172/jci.insight.136437. JCI Insight. 2020. PMID: 32255769 Free PMC article.
Valuing the benefits of new anticancer drugs.
Lawrence NJ, Salkeld G, Stockler MR, Karikios D. Lawrence NJ, et al. Med J Aust. 2016 Jun 20;204(11):403-5. doi: 10.5694/mja15.01362. Med J Aust. 2016. PMID: 27318395 No abstract available.
97 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page